Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 03, 2022 10:17 ET | Source: BlueSphere Bio

BlueSphere Bio Data to be Presented at the 37th Society for Immunotherapy of Cancer (SITC) Annual Meeting

PITTSBURGH, Nov. 03, 2022 (GLOBE NEWSWIRE) -- BlueSphere Bio, a T-cell receptor (TCR) T-cell therapy company developing a powerful TCR discovery platform and novel therapeutic candidates for...
October 04, 2022 10:17 ET | Source: BlueSphere Bio

BlueSphere Bio Appoints Keir Loiacono as Chief Executive Officer

PITTSBURGH, Oct. 04, 2022 (GLOBE NEWSWIRE) -- BlueSphere Bio, a T-cell receptor (TCR) T-cell therapy company developing a powerful TCR discovery platform and novel therapeutic candidates for...
September 26, 2022 09:45 ET | Source: BlueSphere Bio

BlueSphere Bio Presents Data Demonstrating Efficiency of Parallel TCR Capture and Bioinformatics Platforms at 7th Annual CAR-TCR Summit

PITTSBURGH, Sept. 26, 2022 (GLOBE NEWSWIRE) -- BlueSphere Bio, a T-cell receptor (TCR) T-cell therapy company developing a powerful TCR discovery platform and novel therapeutic candidates for...
September 19, 2022 10:30 ET | Source: BlueSphere Bio

BlueSphere Bio to Present at the 7th Annual CAR-TCR Summit

PITTSBURGH, Sept. 19, 2022 (GLOBE NEWSWIRE) -- BlueSphere Bio, a T-cell receptor (TCR) T-cell therapy company developing a powerful TCR discovery platform and novel therapeutic candidates for...
June 13, 2022 11:40 ET | Source: BlueSphere Bio

BlueSphere Bio to Present a Corporate Overview at the 2022 BIO International Convention

PITTSBURGH, June 13, 2022 (GLOBE NEWSWIRE) -- BlueSphere Bio, a T-cell receptor (TCR) T-cell therapy company developing a powerful TCR discovery platform and novel therapeutic candidates for...
May 25, 2022 10:17 ET | Source: BlueSphere Bio

BlueSphere Bio Data to be Presented at the 2022 Joint ASTCT + EBMT Basic and Translational Scientific Retreat

PITTSBURGH, May 25, 2022 (GLOBE NEWSWIRE) -- BlueSphere Bio, a T-cell receptor (TCR) T-cell therapy company developing a powerful TCR discovery platform and novel therapeutic candidates for patients...
April 26, 2022 10:17 ET | Source: BlueSphere Bio

BlueSphere Bio Appoints Robert Keefe, Ph.D. as Chief Development Officer

PITTSBURGH, April 26, 2022 (GLOBE NEWSWIRE) -- BlueSphere Bio, a T-cell receptor (TCR) T-cell therapy company developing a powerful TCR discovery platform and novel therapeutic candidates for...
April 08, 2022 13:05 ET | Source: BlueSphere Bio

BlueSphere Bio Presents New Data Supporting the Potential of its TCXpress™ Platform at the 2022 AACR Meeting

TCXpress™ identified a diverse set of novel T-cell receptors (TCRs) with in vitro reactivity against the minor histocompatibility antigen HA-1, from a single donor Data support the broad potential of...
March 15, 2022 10:17 ET | Source: BlueSphere Bio

BlueSphere Bio Data to be Presented at the 2022 American Association for Cancer Research Annual Meeting

PITTSBURGH, March 15, 2022 (GLOBE NEWSWIRE) -- BlueSphere Bio, a T-cell receptor (TCR) T-cell therapy company developing a revolutionary TCR discovery platform and novel therapeutic candidates for...
February 08, 2022 10:17 ET | Source: BlueSphere Bio

BlueSphere Bio to Present at the BIO CEO & Investor Conference

PITTSBURGH, Feb. 08, 2022 (GLOBE NEWSWIRE) -- BlueSphere Bio, a T-cell receptor (TCR) T-cell therapy company developing a revolutionary TCR discovery platform and novel therapeutic candidates for...